CN105102636B - 用于检测和测定前列腺癌预后的组合物和方法 - Google Patents

用于检测和测定前列腺癌预后的组合物和方法 Download PDF

Info

Publication number
CN105102636B
CN105102636B CN201480015039.9A CN201480015039A CN105102636B CN 105102636 B CN105102636 B CN 105102636B CN 201480015039 A CN201480015039 A CN 201480015039A CN 105102636 B CN105102636 B CN 105102636B
Authority
CN
China
Prior art keywords
prostate cancer
sample
subject
expression
algorithm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480015039.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105102636A (zh
Inventor
M·阿尔比塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoGenomics Laboratories Inc
Original Assignee
NeoGenomics Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeoGenomics Laboratories Inc filed Critical NeoGenomics Laboratories Inc
Publication of CN105102636A publication Critical patent/CN105102636A/zh
Application granted granted Critical
Publication of CN105102636B publication Critical patent/CN105102636B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201480015039.9A 2013-03-14 2014-03-13 用于检测和测定前列腺癌预后的组合物和方法 Expired - Fee Related CN105102636B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785375P 2013-03-14 2013-03-14
US61/785,375 2013-03-14
PCT/US2014/025860 WO2014160120A1 (en) 2013-03-14 2014-03-13 Compositions and methods for detecting and determining a prognosis for prostate cancer

Publications (2)

Publication Number Publication Date
CN105102636A CN105102636A (zh) 2015-11-25
CN105102636B true CN105102636B (zh) 2019-08-13

Family

ID=51625336

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015039.9A Expired - Fee Related CN105102636B (zh) 2013-03-14 2014-03-13 用于检测和测定前列腺癌预后的组合物和方法

Country Status (6)

Country Link
US (1) US20140336280A1 (enExample)
EP (1) EP2971177B1 (enExample)
JP (1) JP6285009B2 (enExample)
CN (1) CN105102636B (enExample)
CA (1) CA2904088A1 (enExample)
WO (1) WO2014160120A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CN104561303A (zh) * 2014-12-31 2015-04-29 南京卡迪奥密生物技术有限公司 人肿瘤预测性生物标志组合物及其应用
WO2017103047A1 (en) * 2015-12-17 2017-06-22 Institut Curie Use of antisense long non-coding rnas for the diagnosis of prostate cancer
CN106282366A (zh) * 2016-09-09 2017-01-04 北京致成生物医学科技有限公司 一种与前列腺癌相关的分子标记物及其应用
CN106148554A (zh) * 2016-09-09 2016-11-23 北京致成生物医学科技有限公司 一种用于前列腺癌检测的标志物及其在试剂盒中的应用
CN106148556A (zh) * 2016-09-14 2016-11-23 北京致成生物医学科技有限公司 C22orf41在前列腺癌诊断标志物中的应用
CN106282382A (zh) * 2016-09-30 2017-01-04 北京致成生物医学科技有限公司 Loc100128842在制备诊断或预示前列腺癌产品中的用途
JP2019531738A (ja) * 2016-10-14 2019-11-07 ウニヴェルズィテート チューリッヒ 前立腺癌の診断と予後のためのインドールアミン−２，３−ジオキシゲナーゼ アッセイ
JP6812789B2 (ja) * 2016-12-28 2021-01-13 富士通株式会社 情報処理装置、情報処理プログラム、および情報処理方法
CN110760584B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌疾病进展生物标志物及其应用
CN110760585B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌生物标志物及其应用
US20210333280A1 (en) * 2020-04-23 2021-10-28 YatHing Biotechnology Company Limited Methods related to the diagnosis of prostate cancer
US20240011996A1 (en) * 2020-11-24 2024-01-11 Korea Institute Of Science And Technology Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080933A1 (en) * 2009-01-07 2010-07-15 Myriad Genetics, Inc Cancer biomarkers
WO2012135008A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CN102912030A (zh) * 2012-11-08 2013-02-06 端鹏 用于前列腺癌早期诊断的引物对、探针和试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
EP1824995A2 (en) * 2004-11-24 2007-08-29 St. George's Enterprises Limited Diagnosis of prostate cancer
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
EP2373816B1 (en) 2008-12-04 2014-05-21 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20130058925A1 (en) * 2010-02-26 2013-03-07 Board Of Regents, The University Of Texas System Epithelial biomarkers for cancer prognosis
AU2011352167A1 (en) 2010-12-28 2013-07-11 Caris Mpi, Inc. Molecular profiling for cancer
WO2012092490A1 (en) * 2010-12-30 2012-07-05 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
CA2827894A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US20140066325A1 (en) * 2011-03-17 2014-03-06 The Brigham And Women's Hospital, Inc. Protein Biomarkers for the Diagnosis of Prostate Cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080933A1 (en) * 2009-01-07 2010-07-15 Myriad Genetics, Inc Cancer biomarkers
WO2012135008A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CN102912030A (zh) * 2012-11-08 2013-02-06 端鹏 用于前列腺癌早期诊断的引物对、探针和试剂盒

Also Published As

Publication number Publication date
CN105102636A (zh) 2015-11-25
EP2971177A1 (en) 2016-01-20
WO2014160120A1 (en) 2014-10-02
EP2971177B1 (en) 2019-09-11
EP2971177A4 (en) 2016-11-09
HK1213297A1 (zh) 2016-06-30
JP2016514966A (ja) 2016-05-26
CA2904088A1 (en) 2014-10-02
US20140336280A1 (en) 2014-11-13
JP6285009B2 (ja) 2018-02-28

Similar Documents

Publication Publication Date Title
CN105102636B (zh) 用于检测和测定前列腺癌预后的组合物和方法
US10494677B2 (en) Predicting cancer outcome
US10196687B2 (en) Molecular diagnosis and typing of lung cancer variants
JP6049739B2 (ja) 前立腺癌の分類のためのマーカー遺伝子
Agell et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression
JP2016505247A5 (enExample)
WO2012158780A2 (en) Lung cancer signature
JP2011525106A (ja) 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
JP7352937B2 (ja) 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
US20160291024A1 (en) Biomarkers for Ovarian Cancer
CN110573629B (zh) 用于诊断早期胰腺癌的方法和试剂盒
JP6977965B2 (ja) 卵巣癌組織型鑑別方法
JP2020072705A (ja) 膀胱癌を検出するための尿マーカー
JPWO2015137406A1 (ja) 肺扁平上皮癌と肺腺癌の鑑別評価方法
CN113249479B (zh) 胰腺癌相关的lncRNA标志物、探针及检测试剂盒在胰腺癌诊断中的应用
US10066270B2 (en) Methods and kits used in classifying adrenocortical carcinoma
HK1213297B (zh) 用於檢測和測定前列腺癌預後的組合物和方法
JP2021093955A (ja) 膵管内乳頭状粘液性腫瘍由来膵癌または膵癌を検出する方法およびキット
KR20250175547A (ko) FAT1(FAT Atypical Cadherin 1) 또는 ITGB8(Integrin beta 8)을 포함하는 혐색소 신세포암 진단용 바이오마커 조성물
CN117120631A (zh) 滤泡性甲状腺癌特异性标志物
JPWO2015115545A1 (ja) 乳がんの転移又は再発リスクの評価方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213297

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190813

Termination date: 20200313

CF01 Termination of patent right due to non-payment of annual fee